AbCellera rises on rare disease alliance with Rallybio

Rallybio

01/12/2022 13:12

** Shares of AbCellera Biologics Inc  ABCL.O  up 1.63% at
$13.1 premarket
    ** Biotech co ABCL and Rallybio Corporation  RLYB.O 
announce multi-year strategic alliance to develop and
commercialize up to five novel antibody-based therapeutic
targets for rare diseases
    ** With the collaboration, RLYB to add product candidates to
its existing pipeline and provide ABCL option to conduct process
development and clinical manufacturing activities for the
products
    ** ABCL down 10% YTD, as of Wednesday's close 
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))